Michael Collins
Inserm · 32 works · 5,716 citations · h-index 16
Top works
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
- Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
- Enterocolitis due to immune checkpoint inhibitors: a systematic review
- Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
- Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities
- Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors
- Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review
- Iron Supplementation–Induced Phosphaturic Osteomalacia: FGF23 is the Culprit
- The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study
- Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study
- Gastrointestinal Immune Related Adverse Events Associated with Programmed-Death 1 Blockade
- Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis
- Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn’s Disease Recurrence
- Somatostatin analogues for refractory diarrhoea in familial amyloid polyneuropathy
- Anti-PD1-/PDL1-induced chronic intestinal pseudo-obstruction: three cases treated with vedolizumab after corticosteroid failure with mixed results
- SAT0324 ARTICULAR MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB
- Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab
- Notch inhibitors induce diarrhea, hypercrinia and secretory cell metaplasia in the human colon